What are the precautions for taking sorafenib?

Sorafenibis a drug that targets proteins in cancer cells and prevents their growth. Sorafenib is used to treat liver cancer, kidney cancer and thyroid cancer. Sorafenib's brand name is Nexavar. Sorafenib undergoes oxidative metabolism in the liver via CYP3A4 and glucuronidation in the liver and kidney via UGT1A9.

What are the precautions for taking Sorafenib(Sorafenib)?

1.Cardiovascular events. In the HCC studies, the incidence of cardiac ischemia/infarction was 2.7% among patients who received sorafenib and 1.3% among those who received placebo. Across multiple clinical trials, congestive heart failure occurred in 1.9% of patients receiving sorafenib (N=2276). Consider temporarily or permanently discontinuing sorafenib in patients who experience a cardiovascular event.

2.Bleeding. The risk of bleeding may be increased after using sorafenib. inSHARP (HCC), esophageal variceal bleeding (2.4% and 4%) and fatal bleeding from any site (2.4% and 4%) were similar. In the TARGET (RCC) study, bleeding was reported by 15.3%of patients in the sorafenibtreatment group and 8.2%of patients who received placebo. If any bleeding requires medical intervention, consider permanently discontinuing sorafenib. Due to the potential risk of bleeding, treat tracheal, bronchial, and esophageal infiltrates with topical therapy prior to the use of sorafenib in patients with DTC.

3.Hypertension. In the HCC studies, hypertension was reported in 9.4%of patients receiving sorafenib and 4.3%of patients receiving placebo. Monitor blood pressure weekly for the first 6 weeks of taking sorafenib. Thereafter, monitor blood pressure and treat hypertension, if necessary, according to standard medical practice. If severe or persistent hypertension is present, temporary or permanent discontinuation of sorafenib should be considered despite antihypertensive therapy.

4.Skin toxicity. Hand-foot skin reactions and rash arethe most common adverse reactions to sorafenib. Management of cutaneous toxicity may include topical therapy to relieve symptoms, temporary interruption of treatment or dose reduction of sorafenib, or, in severe or persistent cases, permanent discontinuation of sorafenib. There have been reports of serious skin toxicities, includingStevens-Johnsonsyndrome(SJS) and toxic epidermal necrolysis(TEN). These cases can be life-threatening. If SJS or TEN is suspected, discontinue sorafenib.

5.Gastrointestinal perforation. Gastrointestinal perforation has been reported in less than1% of patients taking sorafenib. In some cases, this is not associated with overt intra-abdominal neoplasm. If gastrointestinal perforation occurs, permanently discontinuesorafenib.

6.Concomitant use of warfarin may increase the risk of bleeding. Rare bleeding or an increase in the international normalized ratio (INR) has been reported in some patients taking warfarin while takingsorafenib. Periodically monitor patients taking warfarin concurrently for changes in prothrombin time (PT), INR, or clinical bleeding events.

7.Risk of impaired wound healing. Patients receiving drugs that inhibit the VEGF signaling pathway may experience impaired wound healing. Therefore,sorafenibmay adversely affect wound healing. Discontinue sorafenib at least 10 days before elective surgery. Do not administer this medication for at least 2 weeks after major surgery until the wound has completely healed. The safety of resuming sorafenib after resolution of wound healing complications has not been established.

8.Embryo-Fetal toxicity. Based on its mechanism of action and findings in animals, this product may cause fetal harm when taken by pregnant women. Inform pregnant women and women of reproductive potential of the potential risks to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose of sorafenib. Advise male patients with a female partner of reproductive potential and pregnant partners to use effective contraception during treatment and for 3 months after the last dose of sorafenib. The retail price of Bangladesh Yaopin International Pharmaceutical is about 700 yuan for 0.2g*120 tablets. The retail price of pharmaceuticals in Laos and ASEAN is about 0.2g*56 tablets500yuan. IndiaNATCOPharmaceutical retail price0.2g*120tablets1000yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0